fbpx

molecules of the month

AZD0364

oral reversible ERK1/2 kinase inhibitor

combo eff. w/ MEKi in mKRAS model; in Ph. I

from historical kinase sel. data, SBDD + opt.

Mol. Cancer Ther. Dec. 3, 2020

AstraZeneca, Cambridge, UK

Structure of oral reversible ERK1/2 kinase inhibitor AZD0364
1 min read

AstraZeneca oral reversible ERK1/2 kinase inhibitor


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: